Refoxy Pharmaceuticals is a preclinical biotech company developing small molecule activators of the FOXO3 transcription factor for the treatment of age-related diseases. The company is focused on advancing the development of new therapeutic medicines, starting with idiopathic pulmonary fibrosis (IPF).
Market
Pharmaceuticals
Location
Berlin,
Germany
Coinvestors
Boehringer Ingelheim Venture Fund, Apollo Heath Ventures, NRW.Venture, High-Tech Gründerfonds